A peer-reviewed research has claimed that global ivermectin use can end the COVID-19 pandemic, as the medicine significantly reduces the risk of contracting the deadly respiratory disease when used regularly.
The common antiparasitic ivermectin is being touted as a miracle cure for COVID-19 by doctors and campaigners the world over.
Peer reviewed by medical experts that included three US government senior scientists and published in the American Journal of Therapeutics, the research is the most comprehensive review of the available data taken from clinical, in vitro, animal, and real-world studies.
Led by the Front Line COVID-19 Critical Care Alliance (FLCCC), a group of medical and scientific experts reviewed published peer-reviewed studies, manuscripts, expert meta-analyses, and epidemiological analyses of regions with ivermectin distribution efforts all showing that ivermectin is an effective prophylaxis and treatment for COVID-19.
"We did the work that the medical authorities failed to do, we conducted the most comprehensive review of the available data on ivermectin," said Pierre Kory, MD, president and chief medical officer of the FLCCC. "We applied the gold standard to qualify the data reviewed before concluding that ivermectin can end this pandemic."
A focus of the manuscript was on the 27 controlled trials available in January 2021, 15 of which were randomised controlled trials (RCT's).
Consistent with numerous meta-analyses of ivermectin RCT's since published by expert panels from the UK, Italy, Spain and Japan, they found a large, statistically significant reduction in mortality, time to recovery, and viral clearance in COVID-19 patients treated with ivermectin.
"Our latest research shows, once again, that when the totality of the evidence is examined, there is no doubt that ivermectin is highly effective as a safe prophylaxis and treatment for COVID-19," said Paul E. Marik, founding member of the FLCCC and Chief, Pulmonary and Critical Care Medicine at Eastern Virginia Medical School.
Many regions around the world now recognise that ivermectin is a powerful prophylaxis and treatment for COVID-19. South Africa, Zimbabwe, Slovakia, Czech Republic, Mexico, and India have approved the drug for use by medical professionals.
The results, as seen in this latest study, demonstrate that the ivermectin distribution campaigns repeatedly led to "rapid population-wide decreases in morbidity and mortality".
"We are calling on regional public health authorities and medical professionals around the world to demand that ivermectin be included in their standard of care right away so we can end this pandemic once and for all," Marik noted.
**
The above article has been published from a wire agency with minimal modifications to the headline and text. The Weather Company’s primary journalistic mission is to report on breaking weather news, the environment and the importance of science to our lives. This story does not necessarily represent the position of our parent company, IBM.
Frontiers Removes Controversial Ivermectin Paper Pre-Publication
A review article containing contested claims about the tropical medicine drug as a COVID-19 treatment was listed as “provisionally accepted” on the journal’s website before being removed this week.
This isn’t the first time that Kory and his colleagues at FLCCC have been accused of making unsubstantiated claims about ivermectin.
In December, Kory gave a statement at a US Senate hearing on COVID-19 treatments in which he called ivermectin “effectively a ‘miracle drug’” that could obliterate disease transmission and prevent illness—claims that Associated Press fact-checkers labelled “False” at the time. Kory, who formerly oversaw critical care at the UW Health in Wisconsin, tells The Scientist that he now regrets using “miracle” and other hyperbolic terminology.
Later in December, FLCCC founder Paul Marik, the first author on the now-rejected Frontiers manuscript and a professor at Eastern Virginia Medical School, wrote a paper reviewing ivermectin that included references to debunked papers, including an observational study of ivermectin in COVID-19 patients led by now-discredited Surgisphere Corporation. That study, which had been posted on the preprint server SSRN, was taken down at the request of one of the authors back in May after concerns were raised about the provenance of the company’s data.
There have been a number of trials of ivermectin in COVID-19 patients, although they haven’t met all the criteria that scientists typically deem necessary to generate strong evidence—that is, being randomized, well-controlled trials with hundreds or thousands of patients and findings published in a peer-reviewed journal.
The NIH, which last updated its advice on ivermectin in COVID-19 patients on February 11, 2021, states that most of the studies claiming to show benefits of ivermectin contain “incomplete information and significant methodological limitations, which make it difficult to exclude common causes of bias.”
The agency concludes that “there are insufficient data . . . to recommend either for or against the use of ivermectin for the treatment of COVID-19,” and calls for “adequately powered, well-designed, and well-conducted clinical trials.”
Market Data 
Markets 
AI
